NGL Fine-Chem · forward-looking guidance across the available source record.
Guidance tracker
Management expects to operate within the 15-18% EBITDA margin band going forward, supported by partial price increases already secured from Q1 FY27 and improving competitive dynamics as Chinese players begin raising prices.
Phase 2 (5 clean rooms) plus Phase 1 combined expected to generate 350-400 crore incremental revenue at full utilization, to be achieved over 3-4 years.
European market sales expected to begin in current financial year (FY27) as registrations come through; US market contribution anticipated primarily from FY28 onward.
Company budget targets adding 9-10 new API products per year, with some quarters seeing accelerated additions (5 added in Q4).